Upcoming
October 21–25, 2026 – Denver, CO
American Society of Nephrology (ASN) Kidney Week 2026
Coming soon
Rare Kidney Disease (RKD) Scientific Network (SciNet)
Advancing the Scientific Narrative
Travere Therapeutics is addressing the unmet need for increased scientific and clinical education on RKD, while leading discourse on challenging topics that may advance research, diagnosis, treatment, and outcomes.
Leading the Change in RKD
Travere Therapeutics, as a committed leader in nephrology, remains at the cutting edge of progress and continues to strive to enhance patient outcomes by gathering insights from the RKD community.
Uniting the RKD Community
Travere Therapeutics is building a supportive network and advancing the field of RKD through a meaningful forum that encourages scientific exchange, collaboration, and communication.
The RKD SciNet is driven by our annual summit where we seek to:
- Identify unmet needs in glomerular kidney disease treatment and education
- Engage in case study presentations to further enhance clinical management
- Discuss and debate new advances in clinical trials methodology in rare kidney disease
- Provide a forum for like-minded peers and experts to discuss enhancements to clinical practice
Dive into our collection of engaging RKD podcasts!
Rare Kidney Disease Show
Talking Glomerular Nephropathies Exciting Times Ahead
The Rare Kidney Disease Show is your source for cutting-edge insights, expert perspectives, and pivotal updates in nephrology.
Go to RKD ShowExplore Travere’s research in RKD
Effects of Proteinuria Reduction on Delay of Kidney Failure in Patients With Immunoglobulin A Nephropathy
Speakers: Elle Coe, Alex Mercer, Kevin Carroll, Leah Conley, Daniel Gale, Bruce Hendry, David Pitcher, Crystal Traylor, Jonathan Barratt
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study With UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
Speakers: Wu Gong, Ulysses Diva, Mark Bensink, Xinglei Chai, Yanwen Xie, Sophie Gao, Bruce Hendry, Alex Mercer, Zheng-Yi Zhou, Brad Rovin, Jonathan Barratt
Sparsentan (SPAR) as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Findings From the SPARTAN Trial
Speakers: Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial
Speakers: Michelle N. Rheault, Howard Trachtman, Edward Murphy, and Radko Komers on behalf of the DUPRO steering committee and DUPLEX investigators
Sparsentan Shows Clinically Meaningful Treatment Effects vs Irbesartan in Patients With IgA Nephropathy (IgAN) in the Phase 3 PROTECT Trial
Speakers: Brad Rovin, Jonathan Barratt, Edward Murphy, Rob Geletka, Radko Komers, Vlado Perkovic, on behalf of the DUPRO Steering Committee and PROTECT investigators Presenter: Donald R. Frailey
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Speakers: Howard Trachtman, Rosanna Coppo, Nuhira Ahmed Masthan Ahmed, Kenneth V. Lieberman, Alex Mercer, Michelle Rheault, Moin A. Saleem, Teresa Shafer, Crystal Traylor, Radko Komers
Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Speakers: Priscila Preciado, Laura Kooienga, Robert Malecki, Alex Mercer, Nuhira Ahmed Masthan Ahmed
MA-DS-24-0067 | February 2025